Skip to content
Evigrade
CriticalClass III antiarrhythmic×Atypical antipsychotic – indole derivative

Updated · Methodology

Mechanism

Ziprasidone causes mild to moderate, dose-dependent QT prolongation (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dronedarone, a class III antiarrhythmic, prolongs the heart-rate-corrected QT interval (QTc). According to the European SmPC, the increase is about 10 ms (Bazett). The US label estimates 15 ms at 400 mg twice daily with food, and the effect grows with concentration (dronedarone SmPC, European Medicines Agency, EMA, and label, US Food and Drug Administration, FDA). No studies have looked at ziprasidone together with other QT-prolonging drugs, and an additive effect cannot be excluded (ziprasidone SmPC, AEMPS). Dronedarone moderately inhibits CYP3A4 and strongly inhibits P-glycoprotein (P-gp), a transporter protein (dronedarone SmPC, EMA). CYP3A4 handles only a minor part of ziprasidone metabolism. The strong CYP3A4 inhibitor ketoconazole raised ziprasidone levels by less than 40% without additional QTc prolongation, and the SmPC says no dose adjustment is needed. Ziprasidone may be a P-gp substrate, but the relevance of this in humans is unknown (ziprasidone SmPC, AEMPS, and label, FDA).

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Palpitations, vertigo, fainting or seizures during ziprasidone treatment may signal a malignant arrhythmia (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dronedarone has a low proarrhythmic effect, but arrhythmias can occur when it is combined with drugs that favour arrhythmias or when electrolytes are disturbed. Its adverse reactions include a slow heart rate and QTc prolongation (dronedarone SmPC, European Medicines Agency, EMA). In people taking QT-prolonging drugs, a slow heart rate, low potassium or magnesium, and the use of other such drugs raise the risk of torsade de pointes and sudden death (ziprasidone label, US Food and Drug Administration, FDA).

Management

The combination is contraindicated under the Spanish ziprasidone summaries of product characteristics (SmPCs), for both the originator and the generic. They contraindicate ziprasidone with QT-prolonging drugs and explicitly name class III antiarrhythmics among them. The dronedarone SmPC places dronedarone in this class (ziprasidone SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS; dronedarone SmPC, European Medicines Agency, EMA). The Spanish SmPC also contraindicates ziprasidone in arrhythmias treated with class IA and III antiarrhythmics. The US label contraindicates it with class Ia and III antiarrhythmics as well (ziprasidone SmPC, AEMPS; ziprasidone label, US Food and Drug Administration, FDA). The dronedarone documents contraindicate dronedarone with drugs that prolong the QT interval and can induce torsade de pointes. Ziprasidone is not among their examples. The contraindication still covers it, because the ziprasidone documents describe QT prolongation and rare post-marketing cases of torsade de pointes (dronedarone SmPC, EMA, and label, FDA; ziprasidone SmPC, AEMPS, and label, FDA). Ziprasidone is also contraindicated in known QT prolongation, recent acute myocardial infarction and decompensated heart failure. Dronedarone is contraindicated in current or past heart failure, a heart rate below 50 beats per minute and a Bazett-corrected QT interval (QTc) of 500 ms or more (ziprasidone SmPC, AEMPS; dronedarone SmPC, EMA). Correct potassium and magnesium deficiency before and during dronedarone treatment. During treatment, the SmPC recommends monitoring that includes an electrocardiogram (ECG). Stop dronedarone if the QTc reaches 500 ms or more (dronedarone SmPC, EMA). Correct low potassium and magnesium before starting ziprasidone. If palpitations, vertigo, fainting or seizures appear during treatment, carry out a cardiac assessment including an ECG. If the QTc exceeds 500 ms, the SmPC recommends interrupting ziprasidone (ziprasidone SmPC, AEMPS). No document gives an interval between stopping one drug and starting the other. Dronedarone and its metabolite are fully cleared from plasma 2 weeks after dronedarone is stopped. The mean half-life of oral ziprasidone is 6.6 hours (dronedarone SmPC, EMA; ziprasidone SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dronedarone

Other interactions with Ziprasidone